{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:55:23Z","timestamp":1790258123704,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Federal Institute for Risk Assessment (BfR, Berlin, Germany)"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive Toxicology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.reprotox.2013.07.019","type":"journal-article","created":{"date-parts":[[2013,7,26]],"date-time":"2013-07-26T00:51:35Z","timestamp":1374799895000},"page":"49-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Valproic acid and its derivatives enhanced estrogenic activity but not androgenic activity in a structure dependent manner"],"prefix":"10.1016","volume":"42","author":[{"given":"Sandra","family":"Stempin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Andres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Bumke Scheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Rode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Nau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Lampen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reprotox.2013.07.019_bib0005","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1210\/edrv-13-3-525","article-title":"Analysis of the mechanism of steroid hormone receptor-dependent gene activation in cell-free systems","volume":"13","author":"Bagchi","year":"1992","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1152\/advan.00086.2006","article-title":"Sex steroid effects at target tissues: mechanisms of action","volume":"31","author":"Wierman","year":"2007","journal-title":"Advances in Physiology Education"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0015","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev.physiol.67.040403.120151","article-title":"Regulation of signal transduction pathways by estrogen and progesterone","volume":"67","author":"Edwards","year":"2005","journal-title":"Annual Review of Physiology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0020","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1210\/edrv.20.3.0370","article-title":"Estrogen receptor null mice: what have we learned and where will they lead us","volume":"20","author":"Couse","year":"1999","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0025","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1021\/cr020456u","article-title":"Chemistry and structural biology of androgen receptor","volume":"105","author":"Gao","year":"2005","journal-title":"Chemical Reviews"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0030","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1615\/CritRevEukaryotGeneExpr.v12.i4.10","article-title":"Estrogen receptor action","volume":"12","author":"Nilsson","year":"2002","journal-title":"Critical Reviews in Eukaryotic Gene Expression"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0035","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1210\/endo.138.3.4979","article-title":"Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta","volume":"138","author":"Kuiper","year":"1997","journal-title":"Endocrinology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0040","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1124\/mi.3.5.281","article-title":"Estrogen signaling: a subtle balance between ER alpha and ER beta","volume":"3","author":"Matthews","year":"2003","journal-title":"Molecular Interventions"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0303-7207(02)00364-7","article-title":"Molecular action of androgens","volume":"198","author":"Gobinet","year":"2002","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0050","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0278-6915(02)00018-2","article-title":"The endocrine disrupters: a major medical challenge","volume":"40","author":"Amaral Mendes","year":"2002","journal-title":"Food and Chemical Toxicology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.tox.2004.06.032","article-title":"Endocrine disruptors and human health: is there a problem","volume":"205","author":"Safe","year":"2004","journal-title":"Toxicology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0060","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0952-3278(95)90012-8","article-title":"Fatty acids: ancestral ligands and modern co-regulators of the steroid hormone receptor cell signalling pathway","volume":"52","author":"Sumida","year":"1995","journal-title":"Prostaglandins Leukotrienes and Essential Fatty Acids"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5507\/bp.2011.038","article-title":"Fatty acids as biocompounds: their role in human metabolism, health and disease \u2013 a review. Part 1. Classification, dietary sources and biological functions","volume":"155","author":"Tvrzicka","year":"2011","journal-title":"Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0070","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/carcin\/22.8.1201","article-title":"Effects of docosahexaenoic acid and eicosapentaenoic acid on androgen-mediated cell growth and gene expression in LNCaP prostate cancer cells","volume":"22","author":"Chung","year":"2001","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0075","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1749-6632.2009.04897.x","article-title":"Growth-inhibitory and proapoptotic effects of alpha-linolenic acid on estrogen-positive breast cancer cells","volume":"1171","author":"Kim","year":"2009","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0080","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1210\/mend.11.6.0007","article-title":"Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay","volume":"11","author":"Krey","year":"1997","journal-title":"Molecular Endocrinology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0085","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/ijc.20096","volume":"109","author":"Menendez","year":"2004","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0090","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1210\/en.2002-0180","article-title":"Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells","volume":"144","author":"Graziani","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0095","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1073\/pnas.0402014101","article-title":"Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition","volume":"101","author":"Jansen","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0100","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1038\/sj.onc.1208662","article-title":"Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A","volume":"24","author":"Reid","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0105","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.steroids.2005.07.003","article-title":"Valproate is an anti-androgen and anti-progestin","volume":"70","author":"Death","year":"2005","journal-title":"Steroids"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0110","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0028-3908(85)90028-0","article-title":"Pharmacological evaluation of various metabolites and analogues of valproic acid. Anticonvulsant and toxic potencies in mice","volume":"24","author":"L\u00f6scher","year":"1985","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0115","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","article-title":"Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience","volume":"16","author":"Perucca","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0120","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1034\/j.1399-5618.2003.00031.x","article-title":"Valproate","volume":"5","author":"Bowden","year":"2003","journal-title":"Bipolar Disorders"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0125","first-page":"449","article-title":"Acute migraine: current treatment and emerging therapies","volume":"3","author":"Kalra","year":"2007","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0130","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/archneur.1995.00540270077022","article-title":"Migraine prophylaxis with divalproex","volume":"52","author":"Mathew","year":"1995","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0135","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1021\/tx950216s","article-title":"Further branching of valproate-related carboxylic acids reduces the teratogenic activity, but not the anticonvulsant effect","volume":"9","author":"Bojic","year":"1996","journal-title":"Chemical Research in Toxicology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0140","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.reprotox.2010.11.012","article-title":"Potency ranking of valproic acid analogues as to inhibition of cardiac differentiation of embryonic stem cells in comparison to their in vivo embryotoxicity","volume":"31","author":"de Jong","year":"2011","journal-title":"Reproductive Toxicology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0145","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1021\/tx0502241","article-title":"Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives","volume":"19","author":"Eikel","year":"2006","journal-title":"Chemical Research in Toxicology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0150","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1006\/taap.1999.8770","article-title":"New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives in vitro: activation of the peroxisomal proliferator-activated receptor (PPARdelta)","volume":"160","author":"Lampen","year":"1999","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0014-2999(01)01423-6","article-title":"Peroxisome proliferator-activated receptor delta is a specific sensor for teratogenic valproic acid derivatives","volume":"431","author":"Lampen","year":"2001","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0160","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1124\/mol.104.009340","article-title":"Modulation of peroxisome proliferator-activated receptor delta activity affects neural cell adhesion molecule and polysialyltransferase ST8SiaIV induction by teratogenic valproic acid analogs in F9 cell differentiation","volume":"68","author":"Lampen","year":"2005","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0165","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1600-0773.1991.tb01303.x","article-title":"Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms","volume":"69","author":"Nau","year":"1991","journal-title":"Pharmacology & Toxicology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0170","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0378-4274(99)00177-0","article-title":"AHTN and HHCB show weak estrogenic \u2013 but no uterotrophic activity","volume":"111","author":"Seinen","year":"1999","journal-title":"Toxicology Letters"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0175","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/toxsci\/66.1.69","article-title":"A novel cell line, MDA-kb2, that stably expresses an androgen- and glucocorticoid-responsive reporter for the detection of hormone receptor agonists and antagonists","volume":"66","author":"Wilson","year":"2002","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0180","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0014-2999(98)00462-2","article-title":"Studies on the teratogen pharmacophore of valproic acid analogues: evidence of interactions at a hydrophobic centre","volume":"354","author":"Bojic","year":"1998","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0185","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1023\/A:1015832411981","article-title":"The enantiomers of the valproic acid analogue 2-n-propyl-4-pentynoic acid (4-yn-VPA): asymmetric synthesis and highly stereoselective teratogenicity in mice","volume":"9","author":"Hauck","year":"1992","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0190","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/toxsci\/48.1.55","article-title":"Development of a stably transfected estrogen receptor-mediated luciferase reporter gene assay in the human T47D breast cancer cell line","volume":"48","author":"Legler","year":"1999","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0195","first-page":"725","article-title":"Firefly luciferase gene: structure and expression in mammalian cells","volume":"7","author":"de Wet","year":"1987","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0200","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1210\/endo.139.10.6216","article-title":"Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta","volume":"139","author":"Kuiper","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0205","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jsbmb.2006.06.020","article-title":"Isoflavone metabolites and their in vitro dual functions: they can act as an estrogenic agonist or antagonist depending on the estrogen concentration","volume":"101","author":"Hwang","year":"2006","journal-title":"Journal of Steroid Biochemistry and Molecular Biology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0210","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0215","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1081\/CLT-100102388","article-title":"Multicenter case series of valproic acid ingestion: serum concentrations and toxicity","volume":"38","author":"Spiller","year":"2000","journal-title":"Journal of Toxicology \u2013 Clinical Toxicology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0220","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"G\u00f6ttlicher","year":"2001","journal-title":"EMBO Journal"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0225","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/toxsci\/kfg102","article-title":"UV filters with antagonistic action at androgen receptors in the MDA-kb2 cell transcriptional-activation assay","volume":"74","author":"Ma","year":"2003","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0230","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1210\/jc.2003-030330","article-title":"Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor","volume":"89","author":"Clark","year":"2004","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0235","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2741\/1010","article-title":"Xenoestrogen exposure and mechanisms of endocrine disruption","volume":"8","author":"Singleton","year":"2003","journal-title":"Frontiers in Bioscience"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0240","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1210\/me.2004-0513","article-title":"New modes of action for endocrine-disrupting chemicals","volume":"20","author":"Tabb","year":"2006","journal-title":"Molecular Endocrinology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0245","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1073\/pnas.0308319100","article-title":"Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D","volume":"101","author":"Str\u00f6m","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0250","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","article-title":"Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors","volume":"34","author":"Duenas-Gonzalez","year":"2008","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0255","doi-asserted-by":"crossref","first-page":"37","DOI":"10.14712\/fb2007053020037","article-title":"Valproic acid, a molecular lead to multiple regulatory pathways","volume":"53","author":"Kostrouchov\u00e1","year":"2007","journal-title":"Folia Biologica"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0260","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1158\/1535-7163.MCT-07-0197","article-title":"The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment","volume":"6","author":"Stettner","year":"2007","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0265","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.mce.2003.10.032","article-title":"Antiepileptic drugs inhibit cell growth in the human breast cancer cell line MCF7","volume":"213","author":"Olsen","year":"2004","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0270","doi-asserted-by":"crossref","first-page":"17785","DOI":"10.1074\/jbc.M209430200","article-title":"Sp family of transcription factors is involved in valproic acid-induced expression of Galphai2","volume":"278","author":"Arinze","year":"2003","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0275","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.277.5331.1508","article-title":"Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites","volume":"277","author":"Paech","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0280","first-page":"357","article-title":"Valproic acid, but not its non-teratogenic analogue 2-isopropylpentanoic acid, affects proliferation, viability and neuronal differentiation of the human teratocarcinoma cell line NTera-2","volume":"19","author":"Skladchikova","year":"1998","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0285","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/10408440591007403","article-title":"Mode of action: inhibition of histone deacetylase, altering WNT-dependent gene expression, and regulation of beta-catenin \u2013 developmental effects of valproic acid","volume":"35","author":"Wiltse","year":"2005","journal-title":"Critical Reviews in Toxicology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0290","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/BF00374130","article-title":"Structural bases of the teratogenic effects of the antiepileptic valproic acid, 2-n-propyl-4-pentenic acid, the first structural analogue with significantly higher teratogenic action than VPA","volume":"76","author":"Hauck","year":"1989","journal-title":"Naturwissenschaften"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0295","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.bcp.2004.04.031","article-title":"Histone deacetylase inhibition and estrogen signalling in human breast cancer cells","volume":"68","author":"Margueron","year":"2004","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0300","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1007\/s11064-008-9622-z","article-title":"Regulation of ER alpha signaling pathway in neuronal HN10 cells: role of protein acetylation and Hsp90","volume":"33","author":"Suuronen","year":"2008","journal-title":"Neurochemical Research"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0305","doi-asserted-by":"crossref","first-page":"27586","DOI":"10.1074\/jbc.M303740200","article-title":"Valproate induces replication-independent active DNA demethylation","volume":"278","author":"Detich","year":"2003","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0310","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/carcin\/bgl167","article-title":"Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes","volume":"28","author":"Milutinovic","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0315","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1053\/beem.2001.0120","article-title":"Steroid 5alpha-reductases and 3alpha-hydroxysteroid dehydrogenases: key enzymes in androgen metabolism","volume":"15","author":"Jin","year":"2001","journal-title":"Best Practice and Research. Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0320","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1124\/dmd.107.014662","article-title":"Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line","volume":"35","author":"Valentini","year":"2007","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0325","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1158\/0008-5472.CAN-05-0487","article-title":"Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo","volume":"66","author":"Xia","year":"2006","journal-title":"Cancer Research"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0330","first-page":"1293","article-title":"Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells","volume":"32","author":"Iacopino","year":"2008","journal-title":"International Journal of Oncology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0335","doi-asserted-by":"crossref","first-page":"8563","DOI":"10.1128\/MCB.23.23.8563-8575.2003","article-title":"Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth","volume":"23","author":"Fu","year":"2003","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.reprotox.2013.07.019_bib0340","first-page":"25","article-title":"Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells","volume":"24","author":"Thelen","year":"2004","journal-title":"International Journal of Oncology"}],"container-title":["Reproductive Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623813002608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623813002608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:36:27Z","timestamp":1760189787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890623813002608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":68,"alternative-id":["S0890623813002608"],"URL":"https:\/\/doi.org\/10.1016\/j.reprotox.2013.07.019","relation":{},"ISSN":["0890-6238"],"issn-type":[{"value":"0890-6238","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valproic acid and its derivatives enhanced estrogenic activity but not androgenic activity in a structure dependent manner","name":"articletitle","label":"Article Title"},{"value":"Reproductive Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reprotox.2013.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}